Jump to navigation Jump to search
|Chemical and physical data|
|Molar mass||145.4 kg/mol g·mol−1|
|(what is this?)|
This drug was developed by Morphotek, Inc.
It is targeted at FR-alpha which is overexpressed in some cancers such as ovarian cancer.
- Statement On A Nonproprietary Name Adopted By The Usan Council - Farletuzumab, American Medical Association.
- ClinicalTrials.gov: Phase II Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
- ClinicalTrials.gov: Phase III Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|